

ANNEX 1

FP6-2005-LIFESCIHEALTH-6

Call information (Thematic call)

1. **Specific Programme:** 'Integrating and strengthening the European Research Area'
2. **Activity:** Priority thematic area of research 'Life sciences, genomics and biotechnology for health'.
3. **Call title:** Thematic call in the area of Life sciences, genomics and biotechnology for health
4. **Call identifier:** FP6-2005-LIFESCIHEALTH-6
5. **Date of publication:** 8 July 2005
6. **Closure date:** 9 November 2005 at 17.00 (Brussels local time).
7. **Total indicative budget** EUR 381,6 million, broken down as follows:

Instrument (*)	EUR (millions)
IP or NOE	252,1 — 282,1
STREP or CA or area specific SSA	93,5 — 123,5
Strategic SSA across Thematic priority 1	6

(*) IP = Integrated project; NOE = Network of excellence; STREP = Specific targeted research project; CA = Coordination action; SSA = Specific support action

8. Areas called and Instruments:

Proposals are invited in the following areas, which are described using activity codes only. For the full title and definition of topic, applicants must refer to the Work Programme (Section 1.3 Technical Content). The evaluation of proposals will be based on the full definition of topic as described in the Work Programme. For the topic the instrument to be used is indicated.

i Advanced genomics and its applications for health

a) Fundamental knowledge and basic tools for functional genomics in all organisms

Topic Ref.	Instrument
Gene expression and proteomics	
LSH-2005-1.1.1-1	IP
Structural genomics	
LSH-2005-1.1.2-1	IP
Comparative genomics and population genetics	
LSH-2005-1.1.3-1	IP
LSH-2005-1.1.3-2	IP
LSH-2005-1.1.3-3	IP

Topic Ref.	Instrument
Bioinformatics	
Multidisciplinary functional genomics approaches to basic biological processes	
LSH-2005-1.1.5-1	IP
LSH-2005-1.1.5-2	IP
Across the area	
LSH-2005-1.1.0-1	CA
LSH-2005-1.1.0-2	SSA

(b) Application of knowledge and technologies in the field of genomics and biotechnology for health

Topic Ref.	Instrument
Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches	
LSH-2005-1.2.1-1	IP
LSH-2005-1.2.1-2	STREP
Development of new diagnostics	
LSH-2005-1.2.2-1	IP
LSH-2005-1.2.2-2	STREP
LSH-2005-1.2.2-3	STREP
Development of new in vitro tests to replace animal experimentation	
LSH-2005-1.2.3-1	IP
LSH-2005-1.2.3-2	SSA
LSH-2005-1.2.3-3	SSA
Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies	
LSH-2005-1.2.4-1	IP
LSH-2005-1.2.4-2	IP
LSH-2005-1.2.4-3	STREP
LSH-2005-1.2.4-4	STREP
LSH-2005-1.2.4-5	STREP
LSH-2005-1.2.4-6	STREP
Innovative research in post-genomics, which has high potential for application	
LSH-2005-1.2.5-1	IP
LSH-2005-1.2.5-2	IP
LSH-2005-1.2.5-3	STREP

(i) Combating major diseases**a) Application-orientated genomic approaches to medical knowledge and technologies**

Topic Ref.	Instrument
General	
LSH-2005-2.1.0-1	STREP
Combating, cardiovascular disease, diabetes and rare diseases	
LSH-2005-2.1.1-1	IP
LSH-2005-2.1.1-2	NoE
LSH-2005-2.1.1-3	STREP
LSH-2005-2.1.1-4	STREP
LSH-2005-2.1.1-5	IP
LSH-2005-2.1.1-6	STREP
LSH-2005-2.1.1-7	NoE
LSH-2005-2.1.1-8	STREP
LSH-2005-2.1.1-9	STREP
Combating resistance to antibiotics and other drugs	
LSH-2005-2.1.2-1	IP
LSH-2005-2.1.2-2	STREP
LSH-2005-2.1.2-3	SSA
Studying the brain and combating diseases of the nervous system	
LSH-2005-2.1.3-1	IP
LSH-2005-2.1.3-2	IP
LSH-2005-2.1.3-3	STREP
LSH-2005-2.1.3-4	STREP
LSH-2005-2.1.3-5	SSA
Studying human development and the ageing process	
LSH-2005-2.1.4-1	NoE
LSH-2005-2.1.4-2	SSA

(b) Combating cancer

Topic Ref.	Instrument
LSH-2005-2.2.0-1	IP
LSH-2005-2.2.0-2	STREP
LSH-2005-2.2.0-3	STREP
LSH-2005-2.2.0-4	STREP
LSH-2005-2.2.0-5	STREP
LSH-2005-2.2.0-6	SSA

c) **Confronting the major communicable diseases linked to poverty**

Topic Ref.	Instrument
LSH-2005-2.3.0-1	NoE
LSH-2005-2.3.0-2	NoE
LSH-2005-2.3.0-3	IP
LSH-2005-2.3.0-4	STREP
LSH-2005-2.3.0-5	STREP
LSH-2005-2.3.0-6	SSA/CA
LSH-2005-2.3.0-7	SSA/CA
LSH-2005-2.3.0-8	SSA/CA
LSH-2005-2.3.0-9	SSA/CA

SSAs across Thematic Priority 1

Topic Ref.	Instrument
LSH-2005-3-1	SSA
LSH-2005-3-2	SSA
LSH-2005-3-3	SSA
LSH-2005-3-4	SSA
LSH-2005-3-5	SSA
LSH-2005-3-6	SSA
LSH-2005-3-7	SSA
LSH-2005-3-8	SSA
LSH-2005-3-9	SSA
LSH-2005-3-10	SSA
LSH-2005-3-11	SSA
LSH-2005-3-12	SSA

9. **Minimum number of participants ⁽¹⁾:**

Instrument	Minimum number of participants
IP, NoE, STREP and CA	3 independent legal entities from 3 different MS or AS, with at least 2 MS or ACC.
SSA	1 legal entity from a MS or AS.

⁽¹⁾ MS = Member States of the EU; AS (incl. ACC) = Associated States; ACC = Associated candidate countries.
Any legal entity established in a Member State or Associated State and which is made up of the requested number of participants may be the sole participant in an indirect action.

10. **Restriction on participation:** None.
11. **Consortia agreements:**
- Participants in IP and NOE are required to conclude a consortium agreement.
 - Participants in STREP, CA and SSA resulting from this call are encouraged, but not required, to conclude a consortium agreement.
12. **Evaluation procedure:**
- The evaluation shall follow a single stage procedure;
 - Proposals will not be evaluated anonymously;
 - The evaluation process may involve 'remote' evaluation of proposals;
 - Applicants may be invited to discuss their proposal.
13. **Evaluation criteria:** See Annex B of the work programme for the applicable criteria (including their individual weights and thresholds and the overall threshold) per instrument.
14. **Indicative evaluation and contractual timetable:**
- Evaluation results: expected to be available some 4 months after the closure date
 - Contract signature: it is estimated that the first contracts related to this call will come into force by the end of 2006.
-